Epigenomics AG

EANS-Voting Rights: Epigenomics AG
Release of a voting rights announcement according to article 26, section 1.1 WpHG (Securities Trading Act) with the aim of a Europe-wide distribution

--------------------------------------------------------------------------------
  Notification of voting rights transmitted by euro adhoc. The issuer is
  responsible for the content of this announcement.
-------------------------------------------------------------------------------- 
Person/company obliged to make the notification: 
----------------------------------- 
Name:    Federated Investors Inc.
Place:   Pittsburgh, PA
State:   USA 
Company data:
----------------------- 
Name:    Epigenomics AG
Address: Kleine Präsidentenstraße 1, 10178 Berlin
Place:   Berlin
State:   Deutschland 
Voting Rights: Release of a Voting Rights Notification (§§ 21 et seq. WpHG) in
Accordance with § 26, para. 1 WpHG (German Securities Trading Act) with the Aim
of an Europe-wide Distribution 
Issuer: 
Epigenomics AG
Kleine Präsidentenstr. 1
10178 Berlin
Germany 
Voting Rights Notification: 
On 2 February 2010, Federated Investors Inc., Pittsburgh, PA, USA, in the name
and on behalf of the Federated Kaufmann Fund, Pittsburgh, PA, USA, made the
following notifications regarding the holding of voting rights held in
Epigenomics AG pursuant to § 21 para. 1 WpHG: 
On 28 January 2010 Federated Kaufmann Fund fell below the 15 per cent thresholds
of § 21 para. 1 WpHG and held at this date 14.983 per cent (i.e. 4,404,350
shares with voting rights of the 29,394,724 shares outstanding) in Epigenomics
AG. 
Federated Investors Inc., is the parent company of F II Holdings Inc.,
Pittsburgh, PA, USA, which in turn is the parent company of Federated Equity
Management Company of Pennsylvania. Federated Equity Management Company of
Pennsylvania, an investment adviser registered in the United States under the
Investment Company Act of 1940, acts as Investment Adviser to the Federated
Kaufmann Fund, a Massachusetts Business Trust and Investment Company, as that
term is defined under the Investment Company Act of 1940. 
Date of release: 2 February 2010 
Epigenomics AG
The Executive Board 
Contact: 
Epigenomics AG
Dr. Achim Plum
Senior Vice President Corporate Development
Tel.: +49 (0)30 24345 368
Fax: +49 (0)30 24345 555
Email: achim.plum@epigenomics.com 
end of announcement                               euro adhoc
-------------------------------------------------------------------------------- 

Further inquiry note:


Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade

Original-Content von: Epigenomics AG, übermittelt durch news aktuell

Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: